Today, the US Senate confirmed President Biden’s nominee for National Institutes of Health (NIH) Director, Monica Bertagnolli, MD, who will lead the country’s top medical research institute. “We are thrilled that the US Senate has confirmed Dr. Monica Bertagnolli as the new Director of the NIH, as she is an esteemed leader with an impressive career […]
His wife, Joann, is a retired nurse and also knew that research was going to be the way forward for them and for future generations. To find out about studies near you, go to K2Med.com or Fastertrials.org to find sites around the US.
Washington D.C., Oct 23, 2023- Global Alzheimer’s Platform Foundation, (GAP) is pleased to share that new data from the ground-breaking blood-based and digital biomarker platform study, Bio-Hermes, will be shared by study partner Dr. Robin Wolz, of IXICO, at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference. The data will be presented at Symposium […]
‘Coming in and just answer some questions, and seeing if there’s something that needs to be investigated,’ By: Victor Jorges WPTV5 DELRAY BEACH, Fla. — A Palm Beach County research organization is helping people with their memory for free. Brain Matters Research in Delray Beach is hosting free memory screenings on Tuesday and Wednesday from 9 […]
Brain Matters Research and Neuropsychiatric Research Center of Southwest Florida take Alzheimer’s Disease clinical research on the road By Staff | Oct 4, 2023 Brain Matters Research and Neuropsychiatric Research Center of Southwest Florida will be driving clinical research into the community as they introduce the Memory Machine to Fort Myers. The new Memory Machine will allow […]
People with Down syndrome helped scientists pave the way for Alzheimer’s drugs but are now left out of the treatment. By Hampus Hillerstrom and Jo Ann Simons The clinical trials for new Alzheimer’s disease treatment drugs — which researchers believe will slow the course of the disease over time — offer hope to thousands of […]
By Sydney RoellSARASOTA COUNTY, Fla. (SNN) — In honor of Sept. 21 being World Alzheimer’s Day, a group of Sarasota researchers hosted a free bilingual memory screening. Intercoastal Medical Group Neurology and Research Clinic offered their free, confidential memory screening in English and Spanish on Thursday from 8 a.m. to 3 p.m. at Robert L. Taylor […]
By Janet Lee – Washington Post Consumer Reports has no financial relationship with any advertisers on this site. Doing puzzles, playing memory-boosting games, taking classes and reading are activities that we often turn to for help keeping our brains sharp. But research is showing that what you eat, how often you exercise and the type of exercise you do […]
Free, bilingual screening on World Alzheimer’s Day Intercoastal Medical Group Neurology and Research Clinic will hold a free, bilingual?memory?screening event on World Alzheimer’s Day on Sept. 21 from 8 a.m. to 3 p.m. at Robert L. Taylor Community Complex, 1845 John Rivers St., in Sarasota. The goal of the confidential? screening in English and Spanish […]
Revolutionary Studies, Record Breaking Collaboration, and Promising News on Biomarker Studies Top the Charts at AAIC Washington D.C., Aug 31, 2023— Researchers and leaders from the Global Alzheimer’s Platform Foundation® (GAP) assembled with the world’s leading Alzheimer’s researchers, patient advocates, and clinicians at the annual Alzheimer’s Association International Conference (AAIC). From the memorable week, […]
Jessica Cantu from GAP-Net site El Faro Health and Therapeutics was at the Alzheimer’s Association’s International Conference (AAIC) in Amsterdam and spoke about the creation of the site in Starr County, Texas. En el condado Starr, casi uno en cada cuatro adultos de 65 años de edad en adelante fueron diagnosticados con Alzheimer en el […]
By Cathy Kelly Medicare policymakers have felt that without an effective approved treatment, coverage of amyloid PET scans and APOE4 genetic tests was not warranted. But that is changing. There is more to Medicare coverage for Alzheimer’s treatment than Leqembi, Eisai Co., Ltd. and Biogen, Inc.’s newly-approved amyloid-targeting monoclonal antibody. Now the program also is considering amending restrictive coverage […]
By Cathy Kelly There is no fee to participate, and entries to the registry must be made at baseline and then every six months for up to two years. The Centers for Medicare and Medicaid Services is sticking with its plan to provide broader Medicare coverage for Eisai Co., Ltd. and Biogen, Inc.’s Leqembi for Alzheimer’s – now that […]
The FDA’s approval comes following the recommendation of an FDA advisory committee, which voted unanimously for Leqembi’s full approval earlier this month WASHINGTON, DC, July 6, 2023 — Following a decision from the U.S. Food and Drug Administration (FDA) granting full traditional approval to Leqembi, a disease-modifying Alzheimer’s treatment from Eisai, Global Alzheimer’s Platform Foundation® (GAP) […]
GAP Community Connector, Paula Atkinson, was a guest writer for the Orlando Times and explained why she and GAP are committed to advancing Alzheimer’s clinical research in Black and Brown communities. My grandmother was treated for Alzheimer’s disease, but never diagnosed with it. Why? She was toldby her doctor that it would take too long […]
GAP-Net Site Kerwin Medical Center was featured in Community Impact on the rate of Alzheimer’s disease in Hispanic communities, and how they can help. As part of a nationwide study, Kerwin Medical Center is testing the efficacy of Aducanumab, a drug that helps a type of plaque in the brain and slows memory impairment caused […]
GAP-Net Site K2 Medical Research was featured in the Orlando Times speaking about the rate of Alzheimer’s in the black community, and studies they have that can help. ORLANDO – For the 580,000 Floridians who are living with Alzheimer’s disease, or for the state’s 1.1 million citizens who who serve as unpaid Alzheimer’s caregivers, one […]
GAP President John Dwyer was quoted in the Financial Times talking about how the CMS decision will limit patient access to possible life saving Alzheimer’s treatments. Eisai has warned that mandatory data collection by US health authorities could restrictpatient access to the Japanese drugmaker’s new Alzheimer’s treatment. The company said a decision by Centers for […]
Bio-Hermes won’t just change Alzheimer’s research and diagnostics. It has the potential to save and change lives. WASHINGTON, DC (June 14, 2023) — Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools typically used to detect the disease, like a PET […]
Statement attributed to John M. Dwyer, President of the Global Alzheimer’s Platform Foundation: (WASHINGTON, DC, JUNE 12) – “Last week, I was proud to participate in the open public hearing session at the Food and Drug Administration (FDA)’s Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting in support of full approval of […]
June 8, 2023 Mrs. Rosalynn Carter c/o The Carter Center 453 John Lewis Freedom Parkway NE Atlanta, GA 30307-1406 Dear Mrs. Carter: I read with heartfelt interest the news announcing your dementia diagnosis. Thank you for sharing this news so bravely and publicly. Receiving a dementia or Alzheimer’s diagnosis, and how that news impacts a […]
GAP President John Dwyer was quoted in the Washington Post on the CMS decision. The Centers for Medicare and Medicaid Services said it would cover a class of Alzheimer’s drugs that includes Leqembi if the medicines get traditional approval by drug regulators. (Eisai/Reuters) Medicare officials outlined plans Thursday to broadly cover a new class of […]
News that the U.S. Centers for Medicare and Medicaid Services (CMS) will provide broader coverage for Alzheimer’s treatments lacks specifics; unclear if rural and non-hospital based physicians can participate Statement attributed to John M. Dwyer, President of the Global Alzheimer’s Platform Foundation: (WASHINGTON, DC, JUNE 1) — “It’s too early to celebrate. The U.S. Centers […]
Americans want Congress and the president to step in if CMS doesn’t change its restrictive coverage policy. WASHINGTON (May 23, 2023) — Nearly nine in ten voters favor (87% favor, 77% strongly favor) requiring Medicare to cover the cost of FDA-approved drugs that can slow the progression of Alzheimer’s disease, according to a new poll […]